In the cerebral circulation, endothelin-A receptor activation mediates marked prolonged vasoconstriction whereas endothelin-B (ETB) receptor activation effects dila tion, In contrast to some peripheral vascular beds, ET B recep tor-induced vasoconstriction has not yet been demonstrated in brain vessels, In this study in chloralose-anesthetized cats, with perivascular microapplications of ET B selective agonist (BQ-3020) and antagonist (BQ-788), we investigated whether ET B receptor-mediated constriction could be uncovered in cortical arterioles in vivo. II{ addition, we examined whether normal dilator response to ET B receptor activation is preserved in post ischemic cerebral arterioles. The first microapplication of the selective ET B receptor agonist BQ-3020 (1 fLmollL) onto a pial cortical arteriole elicited marked dilation (caliber increased by 26.3 ± 15.1 % from preinjection baseline). A second application of BQ-3020 (lO-minute interval) onto the same vessel failed to evoke any significant vasomotor response. Subsequent (third and fourth) adventitial microapplication of the ET B receptor agonist on the same arteriolar site effected a significant con striction of cerebral arterioles (-15.3 ± 12.7% and -9.7 ± 6.3% from preinjection baseline, respectively, at 20 and 30 minutes after the first application). The pial arterioles did not display tachyphylaxis to repeated applications of potassium (10 mmoll L). The perivascular application of the ET B receptor antagonist BQ-788 (0.001 to I fLmollL) had no effect on arteriolar caliber Endothelin-l (ET -1) is a 21-amino acid peptide pro duced by vascular endothelial cells and has a high degree of structural homology with the other members of the endothelin family, ET-2 and ET-3 (Yanagisawa et aI.,
per se but blocked both BQ-3020-induced dilation (inhibitory concentration -5 nmollL) and vasoconstriction elicited by re peated activation of ET B receptors. After middle cerebral artery occlusion, most of the arterioles examined displayed a sus tained dilation. The micro application of BQ-3020 into the peri vascular space surrounding postischemic dilated arterioles elic ited a constriction of a similar magnitude to that induced by application of CSF (-17 ± 7% and -17 ± 7% from preinjection baseline, respectively). The adventitial micro application of the ET B receptor antagonist (BQ-788, 0.1 fLmollL) on postocclu sion dilated pial arterioles effected no change in the arteriolar caliber when compared with preinjection baseline. This BQ-788-induced response was significantly different from that in duced by perivascular microinjection of CSF (P < 0.001, analy sis of variance). These investigations indicate that (1) repeated activation of ETB receptors displays tachyphylaxis of the va sodilator response but also uncovers significant constriction of cerebral arterioles in vivo; (2) the ability of BQ-3020 to elicit dilation is lost within 30 minutes of induced focal ischemia; and (3) ETB-mediated contractile tone contributes in a small but significant manner in limiting postischemia dilation of cor tical pial arterioles. Key Words: Endothelin-Endothelin-B receptor-BQ-3020-BQ-788-Cat-Cerebral ischemia Cerebral arterioles-Vasodilation-Vasoconstriction.
1988; Inoue et aI., 1989) . The combination of functional and molecular studies of endothelin receptors has dem onstrated the existence of at least two distinct subtypes, namely endothelin-A (ETA) and endothelin-B (ET B)' The ETA receptor is characterized by a higher affinity toward ET-I than ET-2 and ET-3, whereas the ETB re ceptor displays a similar affinity toward the three endo thelins (Sakurai et aI., 1990; Haynes et aI., 1993; Masaki et aI., 1994) . ETA receptors are mainly located in vascu lar smooth muscle cells, with ET B receptors being pre sent on neuronal, glial, endothelial, and smooth muscle cells. The proportion of each class of endothelin receptor depends on species, vascular bed, and vessel type, and they may mediate contraction or relaxation (Rubanyi and Polokoff, 1994) . In most vascular beds (including cere brovascular), endothelin-induced vasoconstriction nor mally is attributed to activation of ETA receptors (based on the relative potency of endothelin and the ability of selective ETA receptor antagonists to attenuate the re sponses) (Robinson and McCulloch, 1990; Adner et aI., 1993; Feger et aI., 1994 , Patel et aI., 1996c . In contrast, in some peripheral vascular tissue, ET -I-mediated vaso constriction.is resistant to the actions of ET A receptor antagonists and therefore cannot be entirely attributed to ETA receptor activation (Summer et aI." 1992; LaDou ceur et aI., 1993; Davenport and Maguire, 1994) . The function of ET B receptors is more controversial and less well elucidated. It is widely accepted that stimulation of ET B receptors induces vasodilation through generation of the endothelium-derived relaxing factor (nitric oxide and/or prostayclin) (DeNucci et aI., 1988; Karaki et aI., 1993; Kitazono et aI., 1995a) . However, ET B receptor mediated vasoconstriction has been described in some vascular beds but not yet in vessels of the brain (Clozel et aI., 1992; Seo et aI., 1994; Haynes et aI., 1995) . The qualitatively different effects of the endothelins at the ET B receptor have led to subdivision of ET B receptors into ET B 1 receptors (on endothelial cells) that mediate vasodilation f and ET B2 receptors (on smooth muscle cells) that mediate vasoconstriction (Warner et aI., 1993; Masaki et aI., 1994) . The function of the different endo the lin receptor subtypes in vessels is unclear. The ETA receptor has been proposed to mediate constriction on the high-pressure side of the systemic circulation, whereas contractile ET B receptors are more abundant in low-pressure systems such as the pulmonary and venous circulation (Moreland et aI., 1994) . In a defined vessel, the relati ve amount of ETA and contractile ET B receptors varies according to the physiologic or pathologic state of the vessel (Kitazono et aI., 1995b; Adner et aI., 1996; Dagassan et aI., 1996) .
The recent development of selective peptidic and non peptidic antagonists and agonists for ET B receptors pro vides useful tools for the investigation of the physiologic and pathophysiologic role of ET B receptors (Ihara et aI., 1992; Takai et aI., 1992; Ishikawa et aI., 1994; Breu et aI., 1996) . BQ-3020 (N-acetyl-Leu Met Asp Lys Glu Ala Val Tyr Phe Ala His Leu Asp Ile Ile Trp), is a linear ET-l analogue that has demonstrated a -4700-fold se lectivity for the ET B receptor subtype compared with the endothelin ETA receptor in vivo and in vitro (lhara et aI., 1992) . BQ-788 (N-cis-2,6-dimethylpiperidinocarbonyl L-gamma-methylleucyl-D-l-methoxycarbonyltryptopha nyl-D-norleucine) has been identified as a potent selec tive ET B receptor antagonist with a -1000 fold-relative selectivity for the ET B receptor (Ishikawa et aI., 1994) . Both BQ-3020 and BQ-788 display no affinity for re ceptors other than those for endothelins. 1997 To establish a basis for selection of optimal pharma cologic profile (ETA selective or mixed ET AIET B) of endothelin antagonists that could be used in cerebrovas cular disease, the current investigation was designed to examine (1) whether ET B receptor-mediated constriction could be uncovered in cerebral circulation, and (2) whether the vasomotor effects of the ET B agonist and the ET B antagonist on resistance cerebral arterioles were modified by acute focal cerebral ischemia.
MATERIALS AND METHODS

Anesthesia and general preparations
The experiments were carried out on 11 (5 ischemic and 6 nonischemic) adult female cats weighing between 3 and 4 kg. The anesthesia regimen and the surgical procedure are fully described elsewhere (Patel et aI., 1996b) . Briefly, anesthesia was induced with alphaxalone/alphadolone (Saffan, Glaxo Harefield, U.K.) administered into the radial vein. The animals were intubated, and positive-pressure ventilation with nitrous oxide/oxygen (70%/30%) initiated. The femoral artery and vein were cannulated for monitoring arterial blood pressure and ar terial blood gas status and also for administering anesthetic agent and fluids. Anesthesia was maintained using a-chloralose (60 mglkg) and supplemented as required to prevent the return of the corneal reflex during the course of the experiment. The inspired gas mixture was altered to oxygen supplemented air (25% oxygen and arterial blood samples were taken at regular intervals to monitor blood gas status. The animals were main tained normocapnic by adjusting the stroke volume. Metabolic acidosis was controlled by administration of sodium bicarbon ate (8.4% solution) when necessary. Core temperature was measured by a rectal thermometer and maintained at 37°C by means of a thermostatically controlled heating blanket. At the outset of the study, mean arterial pressure was 100 ± 18 mm Hg, arterial carbon dioxide tension was 29. 1 ± 4.0 mm Hg, arterial pH was 7.44 ± 0.05, and arterial oxygen tension was 149 ± 39 mm Hg. These physiologic parameters did not vary significantly during the course of the microapplication study.
The animals were placed in a stereotactic frame and after midline incision, the scalp retracted and sutured onto a metal ring to form a well over the calvaria. The temporalis muscle was retracted and a rectangular craniectomy (-2.5 x 1.5 cm) was made over the parietal cortex using a saline-cooled dental drill. The exposed dura was bathed continuously with mineral oil at 38°C. With the aid of a stereomicroscope (Bausch and Lomb), the dura was excised and then reflected laterally. The preparation was allowed to equilibrate for approximately 30 minutes before any adventitial microapplications were per formed.
Measurement of cerebral resistance arteriolar caliber
Cerebral resistance arteriolar caliber was measured by the method originally developed by Beaz (1966) using an image splitter linked through a closed-circuit video display system. The individual cerebral resistance arterioles were viewed through a stereomicroscope and arteriolar diameter measured from the degree of shear applied to the image splitter to tan gentially oppose the two images. The system was calibrated at x40 and x70 against threads of known diameter, which allows the direct measurement of the vascular diameter in absolute units (micrometers). Vessel diameter was measured before and after injection of substances and monitored over a period of I to 2 minutes. In this study, the size of the arterioles examined ranged between 40 and 290 f.Lm.
Administration of drugs
Artificial CSF was prepared with the following composition: Na+ 156 mmol/L, K+ 3 mmollL, Ca2+ 2.5 mmollL, HC03 � 12 mmollL, and Cl� 152 mmol/L. The pH of the CSF was adjusted to 7.2 by aeration with 95% oxygen-5% carbon dioxide. The agents to be administered by adventitial microapplication were dissolved in CSF. All solutions were prepared freshly on the day of the study. Glass micropipettes (tip diameter 10 to 12 f.Lm) were filled under vacuum with the solution to 'be studied and stored under mineral oil in CSF until required, Adventitial microapplication of substances was carried out using a micro manipulator to position the pipettes in the adventitial space around individual cerebral resistance arterioles, Small volumes (approximately 5 f.LL) were delivered by a pressure ejection system. Repeated application of the agents was performed in the same arteriolar site.
Focal cerebral ischemia studies
The middle cerebral artery (MCA) was exposed using a transorbital approach as previously described by Chen and col leagues (1991) . Briefly, the contents of the left orbit were ex enterated, and the optic foramen was enlarged to expose the dura and the MCA underlying it. The dura was excised, the MCA and its branches were occluded by means of bipolar diathermy, and the artery was sectioned. In each cat, perivas cular microinjections of CSF (pH 7.2), BQ-3020 (1 f.LmollL), and BQ-788 (0.1 f.LmollL) were made at different sites after 30 to 210 minutes of cerebral ischemia. The arterioles studied were located in the ectosylvian and suprasylvian gyri (i.e., the regions supplied by the MCA and representing ischemic pen umbra).
Statistical analysis
All results are expressed as means ± SD of the percentage change in arteriolar caliber from baseline immediately before microapplication of substances. The data were analyzed using a one-way analysis of variance followed by two-tailed Stu dent's unpaired t test using a Bonferroni correction factor for multiple group comparisons.
RESULTS
Adventitial microapplication of BQ-3020
The application of CSF minimally altered pial arterio lar caliber (arteriolar caliber changed by 0.7 ± 4.8% from baseline). The first microapplication of BQ-3020 (l f-LmollL) mediated a marked and transient dilation of pial arterioles (caliber increased by 26.3 ± 15. 1%). A second injection of the ET B receptor antagonist (10 minutes later) at the same site failed to induce any arteriolar dilation. Subsequent (third and fourth) adventitial micro applications of BQ-3020 effected a significant (P < 0.00 I, analysis of variance) constriction of cerebral ar terioles ( Fig. 1 ). Potassium-induced marked dilation, subsequent to repeated injection of BQ-3020, indicated that the pial arterioles were still responsive to vasodilator agents ( Fig. 1) . In separate experiments, repeated adven titial microapplication of potassium (10 mmollL) at the same site did not effect any tachyphylaxis of the dilator response (Fig. 2) . Both CSF-and potassium-induced vas cular effects were independent of the pre injection diam eter (caliber range, 45 to 239 f-Lm). However, the dilation induced by the first microapplication of BQ-3020 was significantly dependent on the preinjection caliber. Pial arterioles with diameter less than 100 f-Lm demonstrated a greater vasodilator response to ET B receptor agonist. The vasoconstriction, observed after repeated activation of ET B receptors, also displayed some size dependency, with arterioles less than 100 f-Lm displaying more pro nounced vasoconstriction.
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FIG. 1. Vasomotor responses of pial arterioles to repeated perivascular microapplication of 80-3020 (1 �moI/L) followed by adventitial application of potassium (1 0 mmoI/L). Data are the percentage change from preinjection baseline in pial arteriolar caliber. ** P < 0.001 , '''p < 0.0001 for the comparison with CSF. Data are presented as mean ± SO. n, number of arterioles examined (n = 16). .
Adventitial microapplication of BQ-788
The subarachnoid perivascular application of the ET B receptor antagonist BQ-788 (0.001 to 1 fLmollL) had no significant effect on pial arteriolar caliber when com pared with CSF injections (Fig. 3) . This BQ-788mediated response was similar, irrespective the size of the vessel examined (62 to 280 fLm).
Adventitial microapplication of BQ-788 and
BQ-3020
Perivascular coapplication of BQ-788 with BQ-3020 (l fLmol/L) in vessels that have not been previously ex amined (preinjection caliber 114 ± 63 fLm [44 to 286 fLm]) produced a dose-dependent attenuation of BQ-3020-induced dilation (Fig. 4) . The concentration of BQ-788 in the coinjectate, which produced half-maximal inhibition of dilatory response to the first application of BQ-3020, was estimated to be approximately 5 nmollL. As shown earlier, the third microapplication of BQ-3020 effected a-IS ± 12% reduction in arteriolar caliber. In separate experiments, when BQ-788 (0.1 fLmollL) was coinjected with BQ-3020, after two previous applications of BQ-3020 alone, no change in arteriolar caliber was observed (0.2 ± 10.2% from baseline). This vasomotor response was significantly different from that elicited by the third application of BQ-3020 alone (P < 0.05).
Middle cerebral artery occlusion-induced alterations in arteriolar diameter
The occlusion of the MCA effected an immediate di lation of all pial arterioles overlying the para sagittal, su prasylvian, and the ectosylvian gyri. This vasodilation was sustained in the parasagittal gyrus (zone irrigated by the anterior cerebral artery) over the entire experimental J Cereh Blood Flow Metah, Vol. 17, No. 11, 1997 period. However, in the ectosylvian and the suprasylvian, few arterioles displayed a transient vasoconstriction. In two cats, a circumscribed zone of marked and sustained vasoconstriction was developed in the ectosylvian gyrus during the 30 minutes after MCA occlusion. Because of the limited availability of vasoconstricted arterioles in our preparation, we elected to investigate the effect of the ET B receptor agonist and antagonist only on dilated pial arterioles located within the suprasylvian and the ecto sylvian gyri (i.e., the region supplied by the MCA and representing ischemic penumbra). The microapplication of CSF (pH = 7.2) on postisch emic dilated arterioles elicited a small vasoconstriction (-17 ± 7%) compared with preinjection caliber (Fig. 5 ).
The magnitude of this response did not alter significantly during the period of 30 to 210 minutes subsequent to induction of ischemia (Fig. 6 ). The perivascular micro application of BQ-3020 (l J.-LmollL) induced a vasocon striction of a similar magnitude to that observed after injection of CSF (Fig. 5) . Furthermore, the magnitude of the response to BQ-3020 did not vary with time after MCA occlusion (Fig. 6) . No relation between the prein jection diameter, which ranged between 49 and 288 J.-Lm, and the BQ-3020-induced response was found.
Adventitial microapplication of BQ-788 after middle cerebral artery occlusion
The adventitial microapplication of the ET B receptor antagonist (BQ-788, 0.1 f-LmollL) on postocclusion di lated pial arterioles elicited no change in the arteriolar caliber when compared with preinjection baseline (Fig.  S) . However, this BQ-788-induced response was signifi cantly different from that induced by perivascular micro injection of CSF (P < 0.001, analysis of variance). The vasomotor response to perivascular application of BQ-788 did not exhibit any marked dependency with respect to the time that had elapsed after occlusion (Fig. 7) or with respect to the size of the arterioles analyzed (diam eter ranged between 41 and 277 J.-Lm).
DISCUSSION
Four novel findings were demonstrated in the current investigation. First, repeated activation of ET B receptors induced not only tachyphylaxis of the vasodilator re sponse, but also significant constriction of cerebral re sistance arterioles in vivo. Second, perivascular microap plication of the selective ET B receptor antagonist (BQ-788) had no effect on pial arteriolar caliber per se but blocked both BQ-3020-induced dilation and BQ-3020mediated vasoconstriction. Third, the ability of BQ-3020 to elicit dilation was lost within 30 minutes of induced focal ischemia. Fourth, ET B-mediated contractile tone contributes in a small but significant manner to limiting postischemia dilation of cortical pial arterioles.
Vasomotor effects of endothelin-B receptor agonist in normal vessels
In the cerebral circulation, the in vitro or in vivo ac tivation of ET B receptors in rat basilar artery or in feline pial arteriole produces a marked vasodilation, which is dependent on the production of nitric oxide (Feger et aI., 1994; Kitazono et aI., 1995a; Schilling et aI., 1995; Patel et aI., 1996c) . In contrast, in some peripheral vascular beds, an ET B receptor also has been linked to the con tractile properties of endothelins. Indeed, it was observed that ET -I-mediated vasoconstriction was resistant to the actions of ETA receptor antagonists, and therefore could not be solely attributed to ETA receptor activation (Sum ner et aI., 1992; McMurdo et a\., 1993; Shetty et aI., 1993; Seo et aI., 1994; Gellai et aI., 1996; Awane-Igata et aI., 1997) . The current study provides the first defini tive evidence of ET B-mediated constriction. Our data demonstrate that a single perivascular microapplication of selective ETB receptor agonist (BQ-3020, 1 fLmollL) induces vasodilation in cerebral resistance arterioles in the same magnitude to that reported by Patel and col leagues (l996c) in anesthetized cats. This ET B dilator response displays tachyphylaxis, as described by Kitazono and colleagues (l995a) . In addition to this, we demonstrate, for the first time, that subsequent (third and fourth) activations of the ET B receptors (10-minute in terval) induce significant constriction of pial arterioles (Fig. 1) . The fact that repeated perivascular application of potassium revealed a reproducible degree of dilation of pial cortical arterioles and that vasoconstriction was inhibited by selective ET B receptor antagonist (BQ-788, 0.1 fLmollL) further implies that both responses (i.e., tachyphylaxis and vasoconstriction) were induced by specific ET B receptor activation. Evidence from in vivo and in vitro studies has indicated the susceptibility of endothelin receptors to desensitization. In the rat, it has been shown that in the basilar artery, vasodilation was 150 200 markedly attenuated in response to a second application of IRL 1620 (ETB receptor agonist), suggesting desen sitization to vasodilator effect of the ET B receptor ago nist (Kitazono et aI., 1995a) . Nevertheless, no ET B re ceptor-mediated vasoconstriction was reported in this study, perhaps because of the lack of repeated activation of the ET B receptors. In awake rats, ET -1 induced de pressor responses, which are probably mediated by ET B receptors and also display pronounced tachyphylaxis (Le Monnier de Gouville et aI., 1996) . Furthermore, an in vitro study by Clozel and Gray (1995) reports that in epithelium-denuded rat tracheal rings, the ET B receptor exhibited tachyphylaxis, since incubation of the rings for 45 minutes with sarafotoxin S6c (selective ET B agonist) induced desensitization to sarafotoxin S6c. In contrast, tachyphylaxis of the vasomotor response has not been shown to occur after application of some neuropeptides (i.e., calcitonin gene-related peptide, adrenomedullin) known to induce vasodilation in cerebral vessels (Wahl et aI., 1994; Lang et aI., 1997 ). An alternate explanation for the apparent tachyphylaxis to the vasodilation medi ated by ET B receptor agonism is a disruption in vascular endothelial cell function. Repeated challenges with the ET B receptor agonist could have depleted the supply of the endothelial vasorelaxant substances that mediate the response (nitric oxipe or prostayclin) or damage the en dothelial cells. This mechanism also may be consistent with the lack of vasodilation with BQ-3020 after isch emia, since endothelial cell integrity could have been compromised with this insult. Nevertheless, Kitazono and coworkers (1995a) report that pretreatment of the basilar artery with an ET B receptor agonist did not affect acetylcholine-induced vasodilation (which is nitric oxide mediated). This may indicate that tachyphylaxis of the vasodilator response, because of repeated activation of ET B receptors, could not be ascribed to the depletion of nitric oxide.
The varied effect of the endothelins at the ET B recep tor have led to the subdivision of the ET B receptor into ETBl receptors (on endothelial cells), which mediate va sodilation, and ET B2 receptors (on smooth muscle cells), which mediate vasoconstriction (Warner et aI., 1993; Masaki et aI., 1994) . The exact mechanisms underlying the contraction of pial arterioles, found in the current study, after repeated activation of ET B receptors are un known. One hypothesis is that repeated perivascular mi croapplication of BQ-3020 induces desensitization of en dothelial ET B (ET B l) receptors that are vasodilator and thus unmask vasoconstriction mediated by ET B2 recep tors located on smooth muscle. These data argue for a potential role of ET B receptors in pathophysiologic situ ations where release of endogenous agonist is increased.
The identification and characterization of ET B receptor subtypes, if any, would be of great importance to eluci date the function of ET B receptors in the cerebral vascu-lature, especially in resistance arterioles, which play an important role in the regulation of cerebral blood flow.
Vasomotor of effects endothelin-B receptor antago nist in normal vessels. The contribution of the ET B re ceptor in the regulation of normal vessel tone has not been the subject of wide attention. In the current study, perivascular microapplication of the selective ET B recep tor antagonist (BQ-788) had no effect on pial arteriolar caliber (Fig. 3) . This finding suggests that at least at the level of the adventitial surface, there is minimal tone from activation of ET B receptors by endogenous endo thelins. These data are in agreement with the reports of Patel and colleagues (1994, 1996c) who demonstrated that microappiication of both ETA selective and mixed ET AIET B receptor antagonist did not induce any change in feline cerebral resistance arterioles caliber. However, these observations contrast with those reported by Y oshi moto et al. (1990) and Haynes and Webb (1994) , which suggest that there is continuous production of endothe !ins by cerebrovascular endothelium and that there is basal endothelin-mediated tone in the systemic circula tion generally. In the current study and for the first time, the application of BQ-788 onto the cerebral resistance arterioles has been shown to attenuate the vasodilation induced by the ET B receptor agonist. Moreover, BQ-788 was able to block vasoconstriction mediated by repeated perivascular injection of BQ-3020. This is in agreement with the study of Ishikawa and colleagues (1994) in which BQ-788 has been shown to antagonize, with dose dependent manner, the constriction of isolated rabbit pul monary arteries elicited by BQ-3020.
Endothelin-B receptor-mediated vasomotor effects in postischemic vessels
Several lines of evidence indicate the implication of endothelins in the pathogenesis of focal cerebral isch emia, although the precise definition of their pathophysi ologic role has not been fully elucidated (Barone et aI., 1995b; Patel, 1996) . Endothelin receptor antagonists have been shown in some studies to reduce brain damage after induced focal cerebral ischemia (Barone et aI., 1995a; Patel and Wilson, 1995; McAuley et aI., 1996; Patel et aI., 1996a,b) . Critical evaluation of these studies is difficult because of differences in experimental design, species, and receptor antagonists used. Most of the stud ies that have intervened with endothelin receptors an tagonists after induced focal ischemia have focused on the role of ETA receptors as mediator of brain damage. The role of ET B receptors in ischemic disease, however, is still to be elucidated. Endothelin ET B receptors do in part mediate vasospasm in large vessels after subarach noid hemorrhage, since therapeutic intervention with a mixed endothelin ET A/ET B receptor antagonist was shown to be more effective than with an endothelin ETA receptor antagonist alone (Zuccarello et aI., 1994) . More-over, it has been shown that there is an increase in ET B receptor agonist binding sites in basilar arteries after ex perimental subarachnoid hemorrhage, which may indi cate a potential role of ET B receptors in these pathologic conditions (Roux et aI., 1995; Hino et aI., 1996) . In our investigation, we addressed the implication of ET B re ceptor in vasomotor disturbances associated with acute focal cerebral ischemia. Perivascular microinjection of CSF (pH 7.2) onto dilated pial arterioles within the isch emic territory elicited small reduction in arteriolar cali ber. This is most likely caused by the acidotic milieu within the MCA territory rendering the ,exogenously ap plied CSF alkalotic by comparison. The direct adventitial application of BQ-3020 onto dilated arterioles after MCA occlusion showed that ET B receptor-induced dila tion, in normal pial arterioles, is lost in postischemic vessels. This indicates that the ET B receptor-induced vascular effects may vary in pathologic situations such as acute stroke. More importantly, the BQ-788-mediated effects in dilated arterioles, compared with the responses induced by CSF (vehicle), suggest that ETB receptors participate significantly in restricting postischemic dila tion of cortical arterioles in the ischemic penumbra ( Fig.   6 ). Nonetheless, this contribution of ET B receptors in limiting vasodilation is less pronounced compared with that of ET� receptors described by Patel et al. (1996b) .
These findings suggest that the use of broad-spectrum endothelin receptor antagonist (i.e., mixed endothelin ET A /ET B receptor antagonist) would be of greater ben efit in reversing the increased cerebrovascular tone re sulting from the release of endogenous endothelins in acute stroke.
